A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of pertuzumab (rhuMab 2C4) in combination with gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer

Trial Profile

A phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy of pertuzumab (rhuMab 2C4) in combination with gemcitabine and the effect of tumor-based HER2 activation in subjects with platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2015

At a glance

  • Drugs Pertuzumab (Primary) ; Gemcitabine
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 21 Oct 2014 New source identified and integrated (ClinicalTrials.gov record: NCT00096993)
    • 09 Nov 2009 Results have been presented in the Journal of Clinical Oncology.
    • 01 Jul 2008 Results presented at the American Society of Clinical Oncology (ASCO) 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top